8|3|Public
25|$|Both ROS-elevating and ROS-eliminating {{strategies}} {{have been developed}} with the former being predominantly used. Cancer cells with elevated ROS levels depend heavily on the antioxidant defense system. ROS-elevating drugs further increase cellular ROS stress level, either by direct ROS-generation (e.g. motexafin gadolinium, elesclomol) or by agents that abrogate the inherent antioxidant system such as SOD inhibitor (e.g. ATN-224, 2-methoxyestradiol) and GSH inhibitor (e.g. PEITC, buthionine sulfoximine (BSO)). The result is an overall increase in endogenous ROS, which when above a cellular <b>tolerability</b> <b>threshold,</b> may induce cell death. On the other hand, normal cells appear to have, under lower basal stress and reserve, a higher capacity to cope with additional ROS-generating insults than cancer cells do. Therefore, the elevation of ROS in all cells {{can be used to}} achieve the selective killing of cancer cells.|$|E
50|$|The CBoC is Chile's {{monetary}} authority and its monetary policy {{is guided by}} an inflation targeting regime, which is fully in place since 1999. Specifically, the CBoC pursues an inflation target of 3%, with a tolerance range of 1% (above or below), {{with the objective of}} anchoring market expectations in a two-year horizon. Decisions on the monetary policy rate (MPR), the reference interest rate for the economy, usually take place on a monthly basis in the monetary policy meetings, although extraordinary meetings can be called. If inflation expectations are diverging from the 3% target or if there are events since the previous meeting with an anticipated effect in the price level, the CBoC might change the MPR. The monetary policy is carried out through the daily interbank interest rate.Inflation has followed a relatively stable trajectory since the inception of the targeting regime, remaining under 10% ever since; yearly inflation only surpassed the <b>tolerability</b> <b>threshold</b> of 4% in 2007 and 2008, with respective readings of 4.4% and 8.7% in historical terms.|$|E
40|$|Objectives. The {{objectives}} {{of this study}} were 1) to evaluate the effect of different right atrial electrode locations on the efficacy of low energy transvenous defibrillation with an implantable lead system; and 2) to qualitate and quantify the discomfort from atrial defibrillation shocks delivered by a clinically relevant method. Background. Biatrial shocks result in the lowest thresholds for transvenous atrial defibrillation, but the optimal right atrial and coronary sinus electrode locations for defibrillation efficacy in humans have not been defined. Methods. Twenty- eight patients (17 men, 11 women) with chronic atrial fibrillation (AF) (lasting ≤ 1 month) were studied. Transvenous atrial defibrillation was performed by delivering R wave-synchronized biphasic shocks with incremental shock levels (from 180 to 400 V in steps of 40 V). Different electrode location combinations were used and tested randomly: the anterolateral, inferomedial right atrium or high right atrial appendage to the distal coronary sinus. Defibrillation thresholds were defined in duplicate by using the step-up protocol. Pain perception of shock delivery was assessed by using a purpose-designed questionnaire; sedation was given when the shock level was unacceptable (<b>tolerability</b> <b>threshold).</b> Results. Sinus rhythm was restored in 26 of 28 patients by using {{at least one of the}} right atrial electrode locations tested. The conversion rate with the anterolateral right atrial location (21 [81 %] of 26) was higher than that with the inferomedial right atrial location (8 [50 %] of 16, p 0. 05). The mean defibrillation thresholds for the high right atrial appendage, anterolateral right atrium and inferomedial right atrium were all significantly different with respect to energy (3. 9 ± 1. 8 J vs. 4. 6 ± 1. 8 J vs. 6. 0 ± 1. 7 J, respectively, p < 0. 05) and voltage (317 ± 77 V vs. 348 ± 70 V vs. 396 ± 66 V, respectively, p < 0. 05). Patients tolerated a mean of 3. 4 ± 2 shocks with a <b>tolerability</b> <b>threshold</b> of 255 ± 60 V, 2. 5 ± 1. 3 J. Conclusions. Low energy, transvenous defibrillation with an implantable defibrillation lead system is an effective treatment for AF. Most patients can tolerate two to three shocks, and, when the staffing shock level (189 V) is close to the defibrillation threshold, they can tolerate on average a shock level of 260 V without sedation. Electrodes should be positioned in the distal coronary sinus and in the high right atrial appendage to achieve the lowest defibrillation threshold, although other locations may be suitable for certain patients. link_to_subscribed_fulltex...|$|E
30|$|This section {{presents}} {{a discussion on}} validating the adoption of existing risk evaluation criteria for landslide phenomena through statistical databases and precedent cases, particularly for defining acceptability and <b>tolerability</b> <b>thresholds.</b>|$|R
40|$|Logistic {{regression}} models are often proposed to describe dose-response relationships in dose-escalation clinical trials {{to determine the}} maximum tolerated dose. In a Bayesian setting, the 1 -parameter continual reassessment method and the 2 -parameter escalation with overdose control designs have been implemented assuming acceptable <b>tolerability</b> <b>thresholds</b> of between 20...|$|R
40|$|ABSTRACT: Quantitative risk {{analysis}} techniques allow {{the comparison of}} {{the likelihood of a}} fatality to the risk tolerance thresholds for different user groups. Avalanche Hazard Indices (AHI) used in New Zea-land utilise encounter probability formulas which produce a score rather than saying what the likelihood of fatalities are, this does not allow comparison with the risk tolerability of users. It has not been possible to make this comparison {{because of the lack of}} quantitative risk tolerance thresholds which meant that there was no reason for the AHI to produce a likelihood of death figure. By replacing the damage variable in the AHI formula with the probability of death if an avalanche occurs and converting current qualitative risk acceptance thresholds into quantitative thresholds it is possible to compare the likelihood of incidents in-volving fatalities with individual and societal risk tolerances. In order to create levels of risk tolerance by user group it has been necessary to look at the available literature on risk tolerance to imposed and ac-cepted risks and societies low tolerance for multiple fatalities. By comparing the probability of individual or societal risk with risk acceptance thresholds for different categories of users it is then possible to see whether mitigations are needed to reduce risk to a level likely to be tolerable to users and society, it should also be possible to ascertain how accurate forecasting and control measures need to be in order stay below the risk <b>tolerability</b> <b>thresholds...</b>|$|R
40|$|AbstractThe anticancer drug Irinotecan (CPT 11) {{is known}} to trigger the {{induction}} of ATP-Binding Cassette (ABC) transporters, responsible for the efflux of the drug and its metabolites outside of the cells. The drug-modulated overexpression of those transporters prevents its accumulation in the intracellular medium, therefore decreasing its efficacy. A critical clinical concern lies {{in the design of}} CPT 11 -based therapeutic strategies which eradicate a maximum number of cancer cells despite their ability to become resistant. In order to address this issue, we supplemented an existing mathematical model of CPT 11 molecular pharmacokinetics–pharmacodynamics (PK–PD) with a new model of CPT 11 -induced overexpression of ABC transporters. We then theoretically optimized exposure to CPT 11 given as a single agent or combined either with ABC transporter inhibitors, or with inhibitors of nuclear factors whose activation is responsible for transporter overexpression. We firstly considered a cancer cell population endowed with the ability of inducing their transporters. For any drug combination, we concluded that the highest concentration of CPT 11 should be administered in order to kill a maximum number of cancer cells, despite the triggering of resistance. We then considered a population of healthy cells which were assumed to be identical to cancer cells except that they were not able to become resistant. Optimal schemes were defined as the ones which maximized DNA damage in cancer cells under the constraint of DNA damage in healthy cells not exceeding a <b>tolerability</b> <b>threshold.</b> The optimal therapeutic strategy consisted in combining CPT 11 with ABC transporter inhibitors as it achieved a complete reversal of resistance by means of the lowest concentrations of CPT 11...|$|E
40|$|International audienceOptimising drug {{delivery}} {{in the general}} circulation targeted towards cancer cell pop- ulations, but inevitably reaching also proliferating healthy cell populations imposes to design optimised drug infusion algorithms in a dynamic way, i. e., controlling the growth of both populations simultaneously {{by the action of}} the drugs in use, wanted for cancer cells, and unwanted for toxic side effects on healthy cells. Towards this goal, we design models and methods, with optional representation of circadian clock control on proliferation in both populations, according to three axes [15, 16]: a) representing the oncologist's main weapons, drugs, and their fates in the organism by molecular-based pharmacokinetic-pharmacodynamic equations; b) representing the cell populations under attack by drugs, and their proliferation dynamics, including in the models molecular and functional targets for the drugs at stake, by physiologically structured equations; c) using numerical algorithms, optimising {{drug delivery}} under different constraints at the whole organism level, representing impacts of multiple drugs with different targets on cell populations. In the present study, two molecular pharmacological ODE models, one for oxali- platin, and one for 5 -Fluorouracil, have been designed, using law of mass action and enzyme kinetics, to describe the fate of these two cytotoxic drugs in the organism. An age-structured PDE cell population model has been designed with drug control. targets to represent the effects of oxaliplatin and 5 -Fluorouracil on the cell cycle in proliferating cell populations. The models for proliferating cell population dynam- ics involve possible physiological fixed (i. e., out of reach of therapeutic influence) circadian clock control, and varying drug control to be optimised, connected with pharmacological models. Concentrations of drugs, represented by outputs of ODEs, are assumed to be homogeneous in the cell populations under attack by cytotoxic drugs. The possi- bility to describe the effects of other drugs, cytostatic (including in this category anti-angiogenic drugs, considered as acting on the G 1 phase, choking its entries and slowing it down), is also presented, but not put in pharmacokinetic equations and actual simulations in this study, that is focused on the combination of 5 -FU and oxaliplatin, a classic therapeutic association in the treatment of colorectal cancer. We then set conditions to numerically solve drug delivery optimisation problems (maximisation of cancer cell kill under the constraint of preserving healthy cells over a <b>tolerability</b> <b>threshold)</b> by considering a trade-off between therapeutic and toxic effects. The observed effects on proliferation are growth exponents, i. e., first eigenvalues of the linear PDE systems, in the two populations, healthy and cancer. The solutions to an optimisation problem taking into account circadian clock control are presented as best delivery time schedules for the two drugs used in combined treatments, to be implemented in programmable delivery pumps in the clinic...|$|E
40|$|Personalizing anticancer {{treatment}} on molecular basis consists in optimizing the therapy {{according to the}} gene expression profiles of healthy and cancer cells of the patient. The molecular differences between normal and tumor tissues are exploited {{in order to maximize}} the treatment efficacy and minimize its toxicities. This PhD thesis presents a combined mathematical and experimental approach to optimize anticancer therapeutic strategies on molecular basis. This approach has been undertaken at first for the personalization of cancer chronotherapeutics, and secondly for the optimization of anticancer therapy in the case of mutated SRC oncogene. Most of the physiological functions in mammals display rhythms of period around 24, also called circadian rhythms. For instance, rest-activity rhythm, core temperature, or intracellular concentrations of metabolic enzymes show variations over the 24 h span. Those rhythms result in variations in the toxicity and efficacy of many anticancer drug with respect to their circadian time of administration. Recent studies highlight the need for chronomodulated injection scheme which would be tailored to the patient's molecular profile. Thus the first sections of this thesis propose a combined experimental and mathematical approach for personalizing cancer chronotherapeutics on molecular basis. The first step consisted in a proof of concept which involved in vitro experiments on human cell culture and in silico mathematical modeling. We focused on the anticancer drug irinotecan (CPT 11), which is currently used in the treatment of colorectal cancer and displays chronotoxicity and chronoefficacy rhythms both in mice and in cancer patients. Its molecular pharmacokinetics (PK) and pharmacodynamics (PD) were studied in human colorectal adenocarcinoma Caco- 2 cells. An ODE-based mathematical model of its PK-PD was built. It guided the design of experiments which were performed in order to estimate parameter values of the model. Optimization procedures were then applied to this data-calibrated model in order to compute theoretically optimal exposure schemes for the Caco- 2 cell line. CPT 11 accumulated in Caco- 2 cells where it was bioactivated into SN 38 under the catalytic activity of carboxylesterases (CES). The pre-incubation of cells with verapamil, a non-specific inhibitor of ATP-Binding Cassette (ABC) transporters, increased CPT 11 intracellular accumulation, thus demonstrating the involvement of those efflux pumps in CPT 11 transport. After cell synchronization by a seric shock which defines the circadian time (CT) 0, circadian rhythm of period 26 h 50 (SD 63 min) were observed for the expression of the three clock genes REV-ERBα, PER 2, and BMAL 1; and of six metabolic genes: the drug target topoisomerase 1 (TOP 1), the activation enzyme CES 2, the deactivation enzyme UGT 1 A 1, and the four ABC transporters ABCB 1, ABCC 1, ABCC 2, ABCG 2. On the contrary, TOP 1 proteic level and activity remained constant. The amount of DNA-bound TOP 1 in the presence of CPT 11 is a PD marker of the drug and displayed circadian rhythms as it was equal to 47 ± 5. 2 % of the total amount of TOP 1 protein after an exposure at CT 14, as compared to 35. 5 ± 1. 8 % after an exposure at CT 28. Parameters of CPT 11 PK-PD model were estimated from experimental data in Caco- 2 cells combined to information from literature by a bootstrap approach. Optimization procedures were then applied to the data-calibrated model in order to compute theoretically optimal exposure schemes for Caco- 2 cells. Synchronized cells were considered as healthy cells and non-synchronized cells as cancer ones as the circadian organization is often disrupted in tumor tissues. The adopted therapeutics strategy consisted in maximizing DNA damage in cancer cells under the constraint that DNA damage in the healthy population remained under a <b>tolerability</b> <b>threshold.</b> We considered administration schemes {{in the form of a}} cell exposure to an initial extracellular concentration of CPT 11, over 1 to 27 h, starting at a particular CT. Numerical procedures predicted that, for all considered doses of CPT 11, the optimal exposure lasted from 3 h 40 to 7 h 10, and started between CT 2 h 10 and CT 2 h 30, a time interval corresponding to 1 h 30 to 1 h 50 before the minimum value of CES activity. A clinical interpretation can be obtained by rescaling to 24 h those results for Caco- 2 cells which displayed a period of 26 h 50. Thus, an optimal administration of CPT 11 to cancer patients should result in the presence of the drug in the blood during 3 h 30 to 6 h 30, starting 1 h 30 to 1 h 40 before the minimum value of CES activity in the patient. The second section of our research works has consisted in adapting the pluridisciplinary approach we have undertaken for optimizing CPT 11 exposure in Caco- 2 cells, for the optimization of CPT 11 administration in mice. Recent experimental studies demonstrated the existence of three classes of mice regarding CPT 11 chronotoxicity. Female mice of the strain B 6 D 2 F 1 represented the first class and showed worst tolerability after an injection of CPT 11 at ZT 3 and best tolerability at ZT 15, where ZT is Zeitgeber Time, ZT 0 defining the beginning of the light phase. Class 2 was constituted by B 6 D 2 F 1 male mice and displayed worst toxicity at ZT 23 and best toxicity at ZT 11. Finally, class 3 was B 6 CBAF 1 female mice and showed worst tolerability at ZT 7 and best tolerability at ZT 15. Our combined in vivo and in silico approach aimed at characterizing the three chronotoxicity classes at the molecular level and at designing optimal administration schemes for each of them. The mathematical model which was built for Caco- 2 cell culture was adapted to design a whole body physiologically based model of CPT 11 PK-PD. Parameters were estimated for class 2 by fitting both blood and tissular pharmacokinetics data and measurements of circadian rhythms of proteins involved in CPT 11 pharmacology. The calibrated model fitted the biological data. Similar parameter estimations are ongoing for classes 1 and 3. Once three parameter sets are estimated, their comparaison will allow the determination of differences in protein activities and therefore the molecular characterization of the three classes. The next step consists in applying optimization procedures to the calibrated whole body model in order to design theoretically optimal administration schemes for each class. The second project presented in this thesis focuses on the tyrosine kinase SRC, which is deregulated in numerous cancer diseases. Recent studies showed that SRC exerted a control on the mitochondrial pathway of apoptosis in NIH- 3 T 3 mice fibroblasts which were transfected with the oncogene v-src, whereas this control was not observed in parental NIH- 3 T 3 cells. SRC activated the RAS / RAK / MEK 1 / 2 / ERK 1 / 2 pathway which enhanced the phosphorylation of the pro-apoptotic enzyme BIK, thus leading to the protein degradation by the proteasome. As a result, BIK protein expression was low in v-src transformed fibroblasts which possibly contributed to the resistance of those cells to most apoptotic stresses. Our work consisted in designing optimal therapeutics strategies in which parental NIH- 3 T 3 fibroblasts stands for healthy cells and v-src transformed ones for cancer cells. Once again, a combined experimental and mathematical approach was undertaken. First, we built a model for BIK kinetics in non-apoptotic conditions and fitted its parameters to existing experimental data. Estimated parameter values confirmed that SRC-dependent phosphorylation of BIK was inactive in normal cells. Then, we biologically and mathematically investigated BIK kinetics in response to a death signal. We showed a relocalization of BIK to the mitochondria in the first hours of staurosporine exposure, whereas BIK protein total amount remained constant during the apoptotic stress. We then conceived a mathematical model of the mitochondrial pathway of apoptosis in NIH- 3 T 3 cells. It modeled molecular interactions between the anti-apoptotic proteins as BCL 2, and the pro-apoptotic enzymes which were divided into three subgroups: the BAX-like effector proteins, the BH 3 -only activator proteins and the BH 3 -only sensitizer proteins. Parameters were estimated by fitting experimental results in normal and v-src transformed fibroblasts. The model reproduced the experimentally-demonstrated fact that pre-incubating v-src fibroblasts with an inhibitor of SRC before staurosporine exposure annihilated the cell resistance. The model predicted that an administration of ABT- 737, an inhibitor of anti-apoptotic proteins, before staurosporine exposure, should not be undertaken in our particular biological systems, which was experimentally validated. Finally, optimization procedures were applied to the model in order to design optimal therapeutics strategies when both normal and cancer cells were exposed to the same drugs. Considered exposure scheme consisted in the administration of staurosporine after an exposure to activator or of proteins of the mitochondrial pathway of apoptosis. Optimal strategies were defined as the ones which maximized the percentage of apoptotic cells in the cancer cell population, under the constraint that that in the healthy population remained below a toxicity threshold. Optimization procedures allowed to conclude that the optimal drug combinaison consisted in exposing cells to staurosporine after an exposure to a chemical able to repress BAX expression such that its concentration in normal cells was below the needed amount to trigger apoptosis, combined either to a repressor of anti-apoptotic proteins, or an inhibitor of SRC. These optimal strategies led to less than 1 % of apoptotic cells in healthy cells, and more than 98 % in cancer cells. Personnaliser les traitements anticancéreux sur base moléculaire consiste à optimiser la thérapie en fonction des profils d'expression de gènes des cellules saines et tumorales du patient. Les différences au niveau moléculaire entre tissus normaux et cancéreux sont exploitées afin de maximiser l'efficacité du traitement et minimiser sa toxicité. Cette thèse propose une approche pluridisciplinaire expérimentale et mathématique ayant pur but la détermination de stratégies anticancéreuses optimales sur base moléculaire. Cette approche est, tout d'abord, mise en œuvre pour la personnalisation de la chronothérapeutique des cancers, puis pour l'optimisation de la thérapie anticancéreuse dans le cas d'une mutation de l'oncogène SRC. La plupart des fonctions physiologiques chez les mammifères présentent une rythmicité circadienne, c'est-à-dire de période environ égale à 24 h. C'est par exemple le cas de l'alternance activité-repos, de la température corporelle, et de la concentration intracellulaire d'enzymes du métabolisme. Ces rythmes ont pour conséquence une variation de la toxicité et de l'efficacité d'un grand nombre de médicaments anticancéreux selon leur heure circadienne d'administration. De récentes études soulignent la nécessité d'adapter les schémas d'injection chronomodulés au profil moléculaire du patient. La première partie de cette thèse propose une approche combinée expérimentale et modélisatrice pour personnaliser sur base moléculaire la chronothérapie. La première étape a consisté en une preuve de concept impliquant des expérimentations in vitro sur cultures de cellules humaines et des travaux de modélisation in silico. Nous nous sommes focalisés sur l'étude de l'irinotecan (CPT 11), un médicament anticancéreux actuellement utilisé en clinique dans le traitement des cancers colorectaux, et présentant des rythmes de chronotoxicité et de chronoefficacité chez la souris et chez l'homme. Sa pharmacocinétique (PK) et pharmacodynamie (PD) moléculaires ont été étudiées dans la lignée de cellules d'adénocarcinome colorectal humain Caco- 2. Un modèle mathématique de la PK-PD moléculaire du CPT 11, à base d'équations différentielles ordinaires, a été conçu. Il a guidé l'expérimentation qui a été réalisée dans le but de d'évaluer les paramètres du modèle. L'utilisation de procédures d'optimisation, appliquées au modèle calibré aux données biologiques, a permis la conception de schéma d'exposition au CPT 11 théoriquement optimaux dans le cas particulier des cellules Caco- 2. Le CPT 11 s'est accumulé dans les cellules Caco- 2 où il a été biotransformé en son métabolite actif le SN 38, sous l'action des carboxylestérases (CES). La pré-incubation des cellules avec du verapamil, un inhibiteur non spécifique des transporteurs ABC (ATP-Binding Cassette) a permis la mise en évidence du rôle de ces pompes d'efflux ABC dans le transport du CPT 11. Après synchronisation des cellules par choc sérique, qui définit le temps circadien (CT) 0, des rythmes circadiens d'une période de 26 h 50 (SD 63 min) ont été mis en évidence pour l'expression de trois gènes de l'horloge circadienne: REV-ERBα, PER 2, et BMAL 1; et six gènes de la pharmacologie du CPT 11 : la cible du médicament la topoisomerase 1 (TOP 1), l'enzyme d'activation CES 2, l'enzyme de désactivation UGT 1 A 1, et les quatre transporteurs ABCB 1, ABCC 1, ABCC 2, ABCG 2. Au contraire, l'expression protéique et l'activité de la TOP 1 sont restées constantes. Enfin, la quantité de TOP 1 liée à l'ADN en présence de CPT 11, un marqueur de la PD du médicament, a été plus importante pour une exposition à CT 14 (47 ± 5. 2 % de la quantité totale de TOP 1), que pour une exposition à CT 28 (35. 5 ± 1. 8 %). Les paramètres du modèle mathématique de la PK-PD du CPT 11 ont ensuite été estimés par une approche de bootstrap, en utilisant des résultats expérimentaux obtenus sur les cellules Caco- 2, combinés aux données de la littérature. Ensuite, des algorithmes d'optimisation ont été utilisés pour concevoir les schémas d'exposition théoriquement optimaux des cellules Caco- 2 à l'irinotecan. Les cellules synchronisées par un choc sérique ont été considérées comme les cellules saines et les cellules non-synchronisées ont joué le rôle de cellules cancéreuses puisque l'organisation circadienne est souvent perturbée dans les tissus tumoraux. La stratégie thérapeutique optimale a été définie comme celle qui maximise l'efficacité sur les cellules cancéreuses, sous une contrainte de toxicité maximale sur les cellules saines. Les schémas d'administration considérés ont pris la forme d'une exposition à une concentration donnée de CPT 11, débutant à un CT particulier, sur une durée comprise entre 0 et 27 h. Les simulations numériques prédisent que toute dose de CPT 11 devrait être optimalement administrée sur une durée de 3 h 40 à 7 h 10, débutant entre CT 2 h 10 et CT 2 h 30, un intervalle de temps correspondant à 1 h 30 à 1 h 50 avant le minimum des rythmes de bioactivation du CPT 11 par les CES. Une interprétation clinique peut être établie en ramenant à 24 h ces résultats pour les cellules Caco- 2 qui présentent une période de 27 h. Ainsi, une administration optimale du CPT 11 chez le patient cancéreux résulterait en une présence du médicament dans le sang pendant 3 h 30 à 6 h 30, débutant de 1 h 30 à 1 h 40 avant le minimum des rythmes d'activité des CES chez le patient. La deuxième étape de nos travaux a consisté à adapter l'approche mise en œuvre pour optimiser l'exposition des cellules Caco- 2 au CPT 11, pour l'optimisation de l'administration du médicament chez la souris. Des études récentes mettent en évidence trois classes de chronotoxicité à l'irinotecan chez la souris. La classe 1, les souris de la lignée B 6 D 2 F 1 femelles, présentent la pire tolérabilité au CPT 11 après une administration à ZT 3, et la meilleure pour une administration à ZT 15, où ZT est le temps de Zeitgeber, ZT 0 définissant le début de la phase de lumière. La classe 2, les souris B 6 D 2 F 1 mâles, montrent une pire heure d'administration à ZT 23 et une meilleure à ZT 11. Enfin, la classe 3, les B 6 CBAF 1 femelles présentent la pire tolérabilité pour une injection à ZT 7, et la meilleure pour ZT 15. Nous avons entrepris une approche pluridisciplinaire in vivo et in silico dont le but est la caractérisation moléculaire des trois classes de chronotoxicité, ainsi que la conception de schémas optimaux d'administration pour chacune d'elles. Le modèle mathématique mis au point pour une population de cellules en culture a été adapté pour la construction d'un modèle "corps entier" à base physiologique de la PK-PD de l'irinotecan. Un ensemble de paramètres a été estimé pour la classe 2, en utilisant deux sortes de résultats expérimentaux: d'une part, les concentrations sanguines et tissulaires (foie, colon, moelle osseuse, tumeur) du CPT 11 administré aux pire et meilleure heures circadiennes de tolérabilité, et d'autre part, les variations circadiennes des protéines de la pharmacologie du médicament dans le foie et l'intestin. Le modèle ainsi calibré reproduit de façon satisfaisante les données biologiques. Cette étude est en cours pour les classes 1 et 3. Une fois les ensembles de paramètres validés pour chacune des trois classes, ils seront comparés entre eux pour mettre en évidence de possibles différences moléculaires. L'étape suivante consiste en l'application d'algorithmes d'optimisation sur le modèle corps entier pour définir des schémas d'administration chronomodulés optimaux pour chaque classe. La deuxième partie de cette thèse s'intéresse à l'étude de la tyrosine kinase SRC, dont l'expression est dérégulée dans de nombreux cancers. Des études récentes montrent un contrôle de SRC sur la voie mitochondriale de l'apoptose dans des fibroblastes de souris NIH- 3 T 3 transfectés avec l'oncogène v-src, cette régulation étant inexistante dans les cellules parentales. L'oncogène SRC active la voie RAS / RAK / MEK 1 / 2 / ERK 1 / 2 qui augmente la vitesse de phosphorylation de la protéine pro-apoptotique BIK, menant ainsi à sa dégradation par le protéasome. La faible expression de BIK résultant de ce mécanisme rendrait ainsi les cellules v-src résistantes à la plupart des stress apoptotiques. Notre étude a consisté à déterminer, par une approche combinée mathématique et expérimentale, les stratégies thérapeutiques optimales lorsque les cellules NIH- 3 T 3 parentales jouent le rôle de cellules saines, et les fibroblastes transformés celui de cellules cancéreuses. Pour cela, nous avons, tout d'abord, construit un modèle mathématique de la cinétique de BIK en conditions non-apoptotiques. L'estimation des paramètres de ce modèle, en utilisant des données expérimentales existantes, confirme que la phosphorylation de BIK sous le contrôle de SRC est inactive dans les cellules normales. L'étude exprimentale de l'évolution de BIK après le signal apoptotique que constitue une exposition à la staurosporine, démontre une relocalisation de BIK aux mitochondries, la concentration totale de la protéine restant constante durant le stress. Nous avons ensuite conçu un modèle mathématique de la voie mitochondriale de l'apoptose mettant en jeu les protéines anti-apoptotiques de type Bcl 2, les protéines effectrices de type BAX, les protéines BH 3 -only activatrices et les BH 3 -only sensibilisatrices. Un ensemble de paramètres a été déterminé pour les cellules NIH- 3 T 3 parentales, et celles transformées v-src, en comparant le modèle aux données expérimentales. Le modèle reproduit le fait expérimentalement démontré que la préincubation des cellules v-src avec un inhibiteur de la tyrosine kinase SRC, avant l'exposition à la staurosporine, annihile la résistance des fibroblastes transformés au stress apoptotique. Le modèle prédit que l'administration de l'ABT- 737, un inhibiteur de protéines anti-apoptotiques, avant l'exposition à la staurosporine, ne devrait pas être entreprise dans notre systéme biologique, ce qui a été expérimentalement validé. Enfin, le modèle a été utilisé dans des procédures d'optimisation pour déterminer la stratégie thérapeutique théoriquement optimale, lorsque les cellules normales et transformées sont exposées aux mêmes médicaments. Les combinaisons médicamenteuses considérées consiste en une exposition à la staurosporine, précédée d'une exposition à des répresseurs ou activateurs d'expression des protéines de la famille Bcl 2. La stratégie optimale est définie comme celle qui maximise le pourcentage de cellules apoptotiques dans les fibroblastes v-src, sous la contrainte que celui dans les cellules normales reste au-dessous d'un seuil de tolérabilité. Les simulations numériques nous permettent de conclure à une combinaison médicamenteuse optimale constituée d'une exposition à la staurosporine, précédée d'une exposition à un répresseur de l'expression de BAX (de manière à diminuer sa concentration en-dessous du seuil apoptotique dans les cellules normales, mais pas dans les cellules cancéreuses), combinée à un répresseur de BCL 2 ou un inhibiteur de tyrosines kinases SRC. Cette stratégie optimale aboutit à moins d' 1 % de cellules apoptotiques dans les cellules saines et plus de 98 % dans les cellules cancéreuses...|$|E

